NewAmsterdam Pharma Company N.V. (NAMS)
(Delayed Data from NSDQ)
$26.69 USD
-0.04 (-0.15%)
Updated Sep 19, 2025 03:59 PM ET
After-Market: $26.74 +0.05 (0.19%) 7:00 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
NAMS 26.69 -0.04(-0.15%)
Will NAMS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NAMS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NAMS
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Tops Revenue Estimates
Wall Street Analysts Predict a 132.5% Upside in NewAmsterdam Pharma Company N.V. (NAMS): Here's What You Should Know
NAMS: What are Zacks experts saying now?
Zacks Private Portfolio Services
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates
Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates
Other News for NAMS
NAMS Crossed Above 20 Day Moving Average on September 18
20 Day Moving Average Resistance appears for NAMS after 0.12% move
Director Makes Strategic Move with NewAmsterdam Pharma Stock Purchase
Is NAMS positioned for a breakout? 50 Day Moving Average Support shows up after advancing 1.66%
NAMS forms 50 Day Moving Average Support on September 15